Compare BLDP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | IRWD |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Canada | United States |
| Employees | 492 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.9M | 741.8M |
| IPO Year | 2009 | 2009 |
| Metric | BLDP | IRWD |
|---|---|---|
| Price | $2.62 | $3.18 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 7 | 5 |
| Target Price | $2.24 | ★ $4.94 |
| AVG Volume (30 Days) | ★ 3.1M | 3.0M |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $14.14 | $57.95 |
| Revenue Next Year | $21.50 | $4.39 |
| P/E Ratio | ★ N/A | $21.17 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.00 | $0.55 |
| 52 Week High | $4.10 | $5.78 |
| Indicator | BLDP | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 33.58 |
| Support Level | $2.55 | $3.08 |
| Resistance Level | $2.92 | $3.53 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 80.12 | 11.70 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.